Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Combinations of psychotherapy with antidepressants are gold-standard psychiatric treatments. They operate through complex and interactional mechanisms, not unlike the reemergent paradigm of psychedelic-assisted psychotherapy, which promising research suggests may also be highly effective in even challenging populations. AREAS COVERED: We review the therapeutic mechanisms behind both conventional and psychedelic paradigms, including the evolution of this knowledge and the associated explanatory frameworks. We explore how psychedelics have provided insights about psychiatric illnesses and treatments over the past decades. We discuss limitations to early explanatory models while highlighting and comparing the psychological and biological mechanisms underlying many psychiatric treatments. METHODS: , 2020, and iterative retrieval of references from recent reviews and clinical trials. EXPERT OPINION: The contextual model of the common factors of psychotherapy provides a powerful perspective on psychotherapy, antidepressants, and psychedelics, as well as 3,4-methylenedioxymethamphetamine (MDMA) and ketamine. It aligns well with key tenets of psychedelic-assisted psychotherapy. Conventional antidepressants and especially psychedelics may improve the efficacy of psychotherapy via neurochemical changes and increased environmental sensitivity. Combined treatments hold significant promise for advancing the knowledge and treatment of many forms of psychopathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ketamine seems to be mainly offered as a stand-alone pharmacological treatment, like conventional antidepressants (Greenway et al., 2020).”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Greenway et al., 2020
Citations
Cites
1 retracted
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05249-5 · Cited by 359 · cited 1×
“phase 2 trials were sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) from 2004–2016, with results indicating substantial improvements in PTSD symptoms and adequate tolerability to the treatment protocol [224].”
MethodSelf-citationRetractedThe Brain's Default Network: Anatomy, Function, and Relevance to Disease
Buckner, R. L., Andrews‐Hanna, J. R., & Schacter, D. L. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1440.011 · Cited by 9,761
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291 · cited 1×
“The global prevalence of psychiatric disorders and their societal impacts are increasing [1,2], and they are now responsible for approximately 28% of illness morbidity worldwide – half of which is attributable to anxiety and depression [2].”
BackgroundFreud, S. (1913) · MacMillan Co eBooks · doi:10.1037/10561-000 · Cited by 5,920
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“rapidly improved depressive symptoms within minutes or hours [173].”
BackgroundCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2×
“psychotherapy in 2006 for OCD [208], promising results have been published for applications in end of life anxiety [148,187,209], smoking cessation [210], treatment-resistant depression [211], as well as to initiate meditation/spiritual”
BackgroundCognitive impairment in depression: a systematic review and meta-analysis
Rock, P. L., Roiser, J. P., Riedel, W. J., & Blackwell, A. D. (2014) · Psychological Medicine · doi:10.1017/s0033291713002535 · Cited by 2,161 · cited 1×
“This may be due to decreased symptomatology (which frequently includes cognitive changes [75]) increasing therapy efficiency [96], amongst other biological or expectancy effects.”
BackgroundThe Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
The Great Psychotherapy Debate: The Evidence for What Makes Psychotherapy Work
Wampold, B. E. (2015) · doi:10.4324/9780203582015 · Cited by 1,773
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
How important are the common factors in psychotherapy? An update
Wampold, B. E. (2015) · World Psychiatry · doi:10.1002/wps.20238 · Cited by 1,728 · cited 6×
“a strong therapeutic alliance is a necessity of all pathways, as is supported by research [85].”
BackgroundInfluentialTransitional objects and transitional phenomena 1 —a study of the first not-me possession 2
Winnicott, D. W. (2018) · Influential Papers from the 1950s · doi:10.4324/9780429475931-14 · Cited by 1,715 · cited 1×
“similar concepts, such as the creation of therapeutic ‘holding environments’ [198], and evidence is mounting that even”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · cited 6×
“psychotherapy including CBT, psychodynamics [130], and existential meaning-making therapies [187], amongst others.”
BackgroundMethodInfluentialDrug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681 · cited 3×
“those with well-established medical uses like benzodiazepines, in terms of both harm to users and harms to others [222].”
BackgroundSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 1×
“described by at least one expert as ‘arguably the most important discovery in half a century’ [16].”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 1×
“psychotherapy in 2006 for OCD [208], promising results have been published for applications in end of life anxiety [148,187,209], smoking cessation [210], treatment-resistant depression [211], as well as to initiate meditation/spiritual”
BackgroundDepression Is the Leading Cause of Disability Around the World
Friedrich, M. J. (2017) · JAMA · doi:10.1001/jama.2017.3826 · Cited by 1,459 · cited 1×
“depressive disorder is the most common psychiatric illness [3], the leading cause of disability [3], and is associated with”
BackgroundCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252 · cited 3×
“Other effects include decreased constraints on cognition [149], which may account for their phenomenological description as amplifiers of mental processes [157].”
BackgroundPilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“psychotherapy in 2006 for OCD [208], promising results have been published for applications in end of life anxiety [148,187,209], smoking cessation [210], treatment-resistant depression [211], as well as to initiate meditation/spiritual”
BackgroundHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203 · cited 10×
“The therapists/monitors are often referred to as guides as a reflection of the desired stance of non-directiveness [137].”
BackgroundInfluentialKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181 · cited 1×
“[27,38,65,66], pointing instead to mechanisms that are shared amongst various illnesses and treatments.”
BackgroundREBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
The brain's default network and its adaptive role in internal mentation
Andrews-Hanna, J. R. (2012) · The Neuroscientist · doi:10.1177/1073858411403316 · Cited by 1,114 · cited 1×
“when individuals are not focused on the immediate environment [150], but rather engaged in self-referential thought [151], or mental time travel [152], for example.”
BackgroundFrank, J. (1993) · doi:10.56021/9780801840678 · Cited by 1,094
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · cited 3×
“For some conditions, like specific phobia, psychotherapy is superior to all other treatments [27].”
BackgroundSome implicit common factors in diverse methods of psychotherapy.
Rosenzweig, S. (1936) · American Journal of Orthopsychiatry · doi:10.1111/j.1939-0025.1936.tb05248.x · Cited by 1,042
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932 · cited 2×
“Indeed, the experiences themselves are often described as highly meaningful [135], even years later [148].”
BackgroundPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 1×
“psychotherapy in 2006 for OCD [208], promising results have been published for applications in end of life anxiety [148,187,209], smoking cessation [210], treatment-resistant depression [211], as well as to initiate meditation/spiritual”
BackgroundNeural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · cited 3×
“of ego dissolution or oceanic boundlessness [140,141], and mystical experiences that strongly resemble those arising naturally [142].”
BackgroundMcHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07757 · Cited by 800 · cited 1×
“symptomatology) may be more improved [69], and many patients prefer psychotherapy [70].”
BackgroundSafety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 3×
“psychotherapy in 2006 for OCD [208], promising results have been published for applications in end of life anxiety [148,187,209], smoking cessation [210], treatment-resistant depression [211], as well as to initiate meditation/spiritual”
BackgroundThe Role of Common Factors in Psychotherapy Outcomes
Cuijpers, P., Reijnders, M., & Huibers, M. J. H. (2019) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050718-095424 · Cited by 748 · cited 3×
“Patients are typically encouraged to engage in various healthpromoting activities, one of the major common factors of psychotherapy [84].”
BackgroundWeinberger, A. H., Gbedemah, M., Martinez, A. M., Nash, D., Galea, S., & Goodwin, R. D. (2018) · Psychological Medicine · doi:10.1017/s0033291717002781 · Cited by 716 · cited 1×
“The global prevalence of psychiatric disorders and their societal impacts are increasing [1,2], and they are now responsible for approximately 28% of illness morbidity worldwide – half of which is attributable to anxiety and depression [2].”
BackgroundCognitive therapy versus medication for depression: treatment outcomes and neural mechanisms
DeRubeis, R. J., Siegle, G. J., & Hollon, S. D. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2345 · Cited by 690
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · cited 4×
“overlap phenomenologically with those induced by MDMA and especially psilocybin [138].”
BackgroundInfluentialMithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674 · cited 2×
“all been proposed as key psychological mechanisms induced by MDMA in a therapeutic context [225].”
BackgroundSelf-citationGaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1439 · Cited by 661 · cited 2×
“a norepinephrine-dopamine reuptake inhibitor (bupropion) [105].”
BackgroundPsychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657 · cited 2×
“music and emotions, mental images, and association of meaning [140,146,197,205].”
BackgroundSustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643 · cited 1×
“It’s efficacy against depression is thought to owe to enhanced neuroplasticity and reversal of stressinduced neuronal changes [169,170].”
BackgroundValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637 · cited 1×
“Questionnaire [138,139], consistently find dramatic perceptual changes like sensory distortions and synesthesia [133], feelings”
BackgroundPeters, S. K., Dunlop, K., & Downar, J. (2016) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2016.00104 · Cited by 611 · cited 1×
“The disintegration of other networks, including the corticostriato-thalamo-cortical circuit of the salience network [155,156], have also been hypothesized as important”
BackgroundA brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605 · cited 3×
“of serotonin, norepinephrine, and/or dopamine [31].”
BackgroundA BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS
Woolley, D. W., & Shaw, E. (1954) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.40.4.228 · Cited by 602 · cited 1×
“tion with its structural similarity to the recently discovered serotonin lead to the first proposal in 1954 that serotonin might play a significant role in mental illness [33,126].”
BackgroundImproving access to psychological therapy: initial evaluation of two UK demonstration sites
Clark, D. M., Layard, R., Smithies, R., Richards, D. A., Suckling, R., & Wright, B. (2009) · Behaviour Research and Therapy · doi:10.1016/j.brat.2009.07.010 · Cited by 599
Richards, D. A., Ekers, D., McMillan, D., Taylor, R. S., Byford, S., Warren, F. C., Barrett, B., Farrand, P. A., Gilbody, S., Kuyken, W., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31140-0 · Cited by 595
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817709585 · Cited by 589 · cited 1×
“music and emotions, mental images, and association of meaning [140,146,197,205].”
BackgroundLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas
Carhart-Harris, R. L., & Friston, K. J. (2010) · Brain · doi:10.1093/brain/awq010 · Cited by 574 · cited 1×
“Links have been made between the DMN and the Freudian conception of ego given its role in one’s sense of self as well as its suppressive effects on lower-level subcortical systems [154].”
BackgroundCuijpers, P., Cristea, I. A., Karyotaki, E., Reijnders, M., & Huibers, M. J. H. (2016) · World Psychiatry · doi:10.1002/wps.20346 · Cited by 572 · cited 1×
“Benefits of psychotherapy, like antidepressants, typically appear after several weeks of treatment [66,67,76], but are more likely to persist post-treatment [77].”
BackgroundTreatment of Depression in Patients With Alcohol or Other Drug Dependence: A Meta-analysis
Nunes, E. V., & Levin, F. R. (2004) · JAMA · doi:10.1001/jama.291.15.1887 · Cited by 532
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525 · cited 1×
“5 mg/kg infusions twice to thrice weekly [178], for months or years [179].”
BackgroundDomino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520 · cited 2×
“Since its discovery in 1962 [171], ketamine found wide-”
BackgroundGriffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488 · cited 1×
“administration (or smoking [136]) or simultaneous administration of monoamine oxidase inhibitors as are found in botanical”
BackgroundConstructing drug effects: a history of set and setting
Hartogsohn, I. (2017) · Drug Science Policy and Law · doi:10.1177/2050324516683325 · Cited by 472 · cited 1×
“ging from modern recreational users to traditional indigenous communities suggests a near universal emphasis on the importance of ‘set and setting’ [195].”
BackgroundThe pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455 · cited 1×
“psychedelics, and indeed the rate of adverse events in PAP studies is comparable to standard psychotherapy [220].”
ResultHuman Pharmacology of MDMA: Pharmacokinetics, Metabolism, and Disposition
de la Torre, R., Farré, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J., & Camí, J. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00009 · Cited by 444
Ketamine – More mechanisms of action than just NMDA blockade
Sleigh, J., Harvey, M., Voss, L., & Denny, B. (2014) · Trends in Anaesthesia and Critical Care · doi:10.1016/j.tacc.2014.03.002 · Cited by 434
Serotonin research: contributions to understanding psychoses
GEYER, M., & VOLLENWEIDER, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.006 · Cited by 427 · cited 1×
“No consensus has yet been reached, but psychedelic states continue to inspire significant fundamental and clinical interest [160].”
BackgroundCuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., Beekman, A. T., & Reynolds, C. F. (2014) · World Psychiatry · doi:10.1002/wps.20089 · Cited by 424 · cited 2×
“Combining antidepressants with psychotherapy to treat depression is often framed in terms of additive benefits via distinct mechanisms, and indeed response rates are typically greater than either in isolation [24], especially in terms of”
BackgroundPhillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418 · cited 2×
“5 mg/kg infusions twice to thrice weekly [178], for months or years [179].”
BackgroundMethodPredicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417 · cited 2×
“For example, a prospective survey of 654 people who used psychedelics found significant improvements in a measure of psychological well-being [216].”
BackgroundSubjective Reports of the Effects of MDMA in a Clinical Setting
Greer, G., & Tolbert, R. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472364 · Cited by 413 · cited 1×
“trolled substance in the United States in 1985 due to widespread recreational use [165], it was employed in thousands of therapy sessions [166].”
BackgroundDijkstra, K., Pieterse, M., & Pruyn, A. (2006) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.2006.03990.x · Cited by 413
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855974 · Cited by 413 · cited 2×
“anxiety and increases the probability of working through challenging experiences to perhaps achieve therapeutic ‘emotional breakthroughs’ [145,194].”
BackgroundPreller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., Liechti, M. E., Seifritz, E., & Vollenweider, F. X. (2017) · Current Biology · doi:10.1016/j.cub.2016.12.030 · Cited by 402 · cited 1×
“dence [146], and rapidly take on personal meaning [147].”
BackgroundPsychedelics, meditation, and self-consciousness
Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M., & Berkovich-Ohana, A. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01475 · Cited by 390 · cited 1×
“disintegration may thus engender a more present-moment state, as neuroimaging studies of meditators suggest [153].”
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., Michel, Y., Brewerton, T. D., & Doblin, R. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112456611 · Cited by 376
Self-citationGribkoff, V. K., & Kaczmarek, L. K. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.021 · Cited by 371
Prediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369 · cited 2×
“Though these studies are unable to prove causality, controlled studies of psilocybin administered without psychotherapy have also found benefits to mood and wellbeing [215].”
BackgroundActive placebos versus antidepressants for depression
Moncrieff, J., Wessely, S., & Hardy, R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003012.pub2 · Cited by 342
Therapeutic Factors in Psychotherapy
Frank, J. D. (1971) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1971.25.3.350 · Cited by 342 · cited 1×
“Some authors thus speak of the creation and application of a ‘therapeutic myth’ between patient and therapist as a key component of psychotherapy [78,89].”
BackgroundHuhn, M., Tardy, M., Spineli, L. M., Kissling, W., Förstl, H., Pitschel-Walz, G., Leucht, C., Samara, M., Dold, M., Davis, J. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.112 · Cited by 333
Furukawa, T. A., Cipriani, A., Cowen, P. J., Leucht, S., Egger, M., & Salanti, G. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30217-2 · Cited by 322 · cited 1×
“pressants found in many studies [106], which may partly result from positive and negative environments being amplified at”
BackgroundLSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320 · cited 3×
“given the increased suggestibility and acutely heightened environmental sensitivity [130,143,183].”
BackgroundResponse to psychotherapy in borderline personality disorder and methylation status of the BDNF gene
Perroud, N., Salzmann, A., Prada, P., Nicastro, R., Hoeppli, M.-E., Furrer, S., Ardu, S., Krejci, I., Karege, F., & Malafosse, A. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.140 · Cited by 320
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308 · cited 1×
“pressants [177], typically administered by repeated 40-minute IV 0.”
BackgroundThe Psychedelic Experience: A Manual Based on the Tibetan Book of the Dead
(1965) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1965.tb71965.x · Cited by 304 · cited 1×
“By forming an explicit rationale for the need and hopes for the treatment [193], which may also be described as creating the therapeutic”
BackgroundEffective connectivity changes in LSD-induced altered states of consciousness in humans
Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J., & Vollenweider, F. X. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815129116 · Cited by 292 · cited 1×
“The disintegration of other networks, including the corticostriato-thalamo-cortical circuit of the salience network [155,156], have also been hypothesized as important”
BackgroundMoore, M., Yuen, H. M., Dunn, N., Mullee, M. A., Maskell, J., & Kendrick, T. (2009) · BMJ · doi:10.1136/bmj.b3999 · Cited by 287 · cited 1×
“[58], which some attribute to antidepressant discontinuation syndrome.”
BackgroundAngermann, C. E., Gelbrich, G., Störk, S., Gunold, H., Edelmann, F., Wachter, R., Schunkert, H., Graf, T., Kindermann, I., Haass, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.7635 · Cited by 283
Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5010-9 · Cited by 280 · cited 1×
“In addition, MDMAassisted psychotherapy has been explored for use in other indications, including social anxiety in autistic adults and anxiety related to life-threatening illness [227], and current or planned trials will evaluate its use for alcohol use disorders and eating disorders.”
BackgroundSelf-citationClassic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates
Barrett, F. S., & Griffiths, R. R. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_474 · Cited by 273
The use of the psychological flexibility model to support psychedelic assisted therapy
Watts, R., & Luoma, J. B. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.12.004 · Cited by 269 · cited 2×
“aged to engage in intention setting [192].”
BackgroundThe hidden therapist: evidence for a central role of music in psychedelic therapy
Kaelen, M., Giribaldi, B., Raine, J., Evans, L., Timmerman, C., Rodriguez, N., Roseman, L., Feilding, A., Nutt, D., & Carhart-Harris, R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4820-5 · Cited by 267
Effects of psilocybin therapy on personality structure
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12904 · Cited by 267 · cited 1×
“[213], and enhanced personality measures of extraversion of openness [214].”
BackgroundInclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature.
Michaels, T. I., Purdon, J., Collins, A., & Williams, M. T. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1824-6 · Cited by 265 · cited 1×
“Such studies should be demographically diverse and include [239], but not be limited to, treatmentresistant subpopulations.”
BackgroundKetamine abuse potential and use disorder
Liu, Y., Lin, D., Wu, B., & Zhou, W. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.05.016 · Cited by 256 · cited 1×
“These latter results are somewhat surprising given that ketamine is a substance of abuse [222], with significantly more harm and potential for physiological dependence than the psychedelics [233].”
BackgroundClassical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256 · cited 1×
“(5HT2A) receptor agonists, whereas others describe this class as classic (or classical) psychedelics [22,23].”
BackgroundHaile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253 · cited 1×
“It’s efficacy against depression is thought to owe to enhanced neuroplasticity and reversal of stressinduced neuronal changes [169,170].”
BackgroundFrom Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder
Liu, B., Liu, J., Wang, M., Zhang, Y., & Li, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00305 · Cited by 249 · cited 2×
“hypothesis, however, has fared less well [63].”
BackgroundLSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.82 · Cited by 247 · cited 1×
“Emotional processing is altered, including reduced recognition of facial expressions of fear [144], and”
BackgroundDistinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247 · cited 2×
“of ego dissolution or oceanic boundlessness [140,141], and mystical experiences that strongly resemble those arising naturally [142].”
BackgroundKetamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246 · cited 1×
“successfully used in the treatment of depression/anxiety [181], PTSD [229], as well as alcohol [230], heroin [231], and cocaine addiction [232].”
MethodLong-term antidepressant use: patient perspectives of benefits and adverse effects
Cartwright, C., Gibson, K., Read, J., Cowan, O., & Dehar, T. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s110632 · Cited by 242
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 240 · cited 4×
“have been described as ‘psychedelics’ [20].”
BackgroundInfluentialModern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236
Cognitive behavioral therapy of obsessive-compulsive disorder
Foa, E. B. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.2/efoa · Cited by 236
Fifty years chlorpromazine: a historical perspective
Ban, T. A. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a922 · Cited by 227 · cited 1×
“This hypothesis has since been essentially discarded, but the shift toward a biological perspective set the stage for the first commercial antipsychotics in 1952 [32,125], which have since superseded psycho-”
BackgroundPatient experience of negative effects of psychological treatment: results of a national survey
Crawford, M. J., Thana, L., Farquharson, L., Palmer, L., Hancock, E., Bassett, P., Clarke, J., & Parry, G. D. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.162628 · Cited by 225
Rhead, J. C. (2018) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2018.1535149 · Cited by 222 · cited 2×
“tions including 40,000 patients were published in this era [129], and many mainstream figures described psychedelics as offering new frontiers for psychiatry and neuroscience [119].”
BackgroundKamenov, K., Twomey, C., Cabello, M., Prina, A. M., & Ayuso-Mateos, J. L. (2017) · Psychological Medicine · doi:10.1017/s0033291716002774 · Cited by 218 · cited 1×
“symptomatology) may be more improved [69], and many patients prefer psychotherapy [70].”
BackgroundDore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1587556 · Cited by 217 · cited 2×
“Ketamine is thus unique in that it has been – and continues to be – utilized within both psychedelic and more conventional paradigms [174,181].”
BackgroundMethodTolerability and adherence issues in antidepressant therapy
Masand, P. S. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80220-5 · Cited by 213 · cited 1×
“such as depression [54], and potential side-effects like impaired sexual functioning [55].”
BackgroundLSD-Assisted Psychotherapy in Patients with Terminal Cancer
Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. (2017) · International Pharmacopsychiatry · doi:10.1159/000467984 · Cited by 209 · cited 4×
“given the increased suggestibility and acutely heightened environmental sensitivity [130,143,183].”
BackgroundInfluentialThe effects of psychotherapy on brain function: A systematic and critical review
Barsaglini, A., Sartori, G., Benetti, S., Pettersson-Yeo, W., & Mechelli, A. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.006 · Cited by 208 · cited 1×
“Indeed, neuroimaging has demonstrated that both psychotherapy and pharmacotherapy engender neural reorganization to a similar extent across many conditions [113].”
BackgroundAlboni, S., van Dijk, R. M., Poggini, S., Milior, G., Perrotta, M., Drenth, T., Brunello, N., Wolfer, D. P., Limatola, C., Amrein, I., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2015.142 · Cited by 207
Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race
Moore, T. J., & Mattison, D. R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.7507 · Cited by 207 · cited 2×
“American adults estimated to have filled a prescription for an antidepressant in 2013 [35,57].”
BackgroundBrown, C., Battista, D. R., Bruehlman, R., Sereika, S. S., Thase, M. E., & Dunbar-Jacob, J. (2005) · Medical Care · doi:10.1097/01.mlr.0000185733.30697.f6 · Cited by 204
Reviewing the Effectiveness of Music Interventions in Treating Depression
Leubner, D., & Hinterberger, T. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.01109 · Cited by 204 · cited 1×
“Music therapy is an effective treatment of mood disorders [202,203], and music forms a core component of PAP in”
BackgroundLSD enhances the emotional response to music
Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., Curran, H. V., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4014-y · Cited by 203 · cited 2×
“dence [146], and rapidly take on personal meaning [147].”
BackgroundThe Therapeutic Value of Lysergic Acid Diethylamide in Mental Illness
Sandison, R. A., Spencer, A. M., & Whitelaw, J. D. A. (1954) · Journal of Mental Science · doi:10.1192/bjp.100.419.491 · Cited by 196 · cited 1×
“the environment, and the patient’s unique psychic structure [131,132].”
BackgroundDakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., Choi, C. J. “., Basaraba, C. N., Pavlicova, M., & Levin, F. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18101123 · Cited by 186 · cited 1×
“successfully used in the treatment of depression/anxiety [181], PTSD [229], as well as alcohol [230], heroin [231], and cocaine addiction [232].”
MethodSkodol, A. E., Stout, R. L., McGlashan, T. H., Grilo, C. M., Gunderson, J. G., Shea, M. T., Morey, L. C., Zanarini, M. C., DYCK, I. R., & Oldham, J. M. (1999) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1999)10:4 · Cited by 181
Amick, H. R., Gartlehner, G., Gaynes, B. N., Forneris, C., Asher, G. N., Morgan, L. C., Coker-Schwimmer, E., Boland, E., Lux, L. J., Gaylord, S., et al. (2015) · BMJ · doi:10.1136/bmj.h6019 · Cited by 181 · cited 1×
“Benefits of psychotherapy, like antidepressants, typically appear after several weeks of treatment [66,67,76], but are more likely to persist post-treatment [77].”
BackgroundLyons, T., & Carhart-Harris, R. L. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117748902 · Cited by 178 · cited 1×
“[213], and enhanced personality measures of extraversion of openness [214].”
BackgroundDreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation
Kraehenmann, R., Pokorny, D., Vollenweider, L., Preller, K. H., Pokorny, T., Seifritz, E., & Vollenweider, F. X. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4610-0 · Cited by 176 · cited 3×
“Domino and his colleagues had initially settled on descriptions such as ‘dreaming’ for ketamine’s effects [171], similar to language employed for psychedelics [133], and indeed the states induced by ketamine”
BackgroundPrevalence of treatment-resistant depression in primary care: cross-sectional data
Thomas, L., Kessler, D., Campbell, J., Morrison, J., Peters, T. J., Williams, C., Lewis, G., & Wiles, N. (2013) · British Journal of General Practice · doi:10.3399/bjgp13x675430 · Cited by 175 · cited 1×
“ing treatments are generally considered effective [5], treatment-resistance is a common and increasing clinical phenomenon [6,7].”
BackgroundAltered network hub connectivity after acute LSD administration
Müller, F., Dolder, P. C., Schmidt, A., Liechti, M. E., & Borgwardt, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.03.005 · Cited by 174 · cited 1×
“increased communication involving visual/auditory systems, may produce perceptual disturbances [158,159].”
BackgroundTHE HISTORY OF THE PSYCHO-ANALYTIC MOVEMENT
FREUD, S. (1918) · The American Journal of the Medical Sciences · doi:10.1097/00000441-191803000-00026 · Cited by 173
Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00650 · Cited by 172 · cited 10×
“Six phase 2 trials were sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) from 2004–2016, with results indicating substantial improvements in PTSD symptoms and adequate tolerability to the treatment protocol [224].”
MethodInfluentialSelf-citationAdvancing psychotherapy and evidence‐based psychological interventions
Emmelkamp, P. M. G., David, D., Beckers, T., Muris, P., Cuijpers, P., Lutz, W., Andersson, G., Araya, R., Banos Rivera, R. M., Barkham, M., et al. (2014) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1411 · Cited by 164 · cited 1×
“often lacking [71], partly because of greater upfront costs and the (generally false) perception of policy-makers that it is not cost-effective [71,72].”
BackgroundZhao, K., Bai, Z. G., Bo, A., & Chi, I. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4494 · Cited by 161 · cited 1×
“Music therapy is an effective treatment of mood disorders [202,203], and music forms a core component of PAP in”
BackgroundKryst, J., Kawalec, P., Mitoraj, A. M., Pilc, A., Lasoń, W., & Brzostek, T. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00097-z · Cited by 159 · cited 2×
“Ketamine is thus unique in that it has been – and continues to be – utilized within both psychedelic and more conventional paradigms [174,181].”
BackgroundA meta-analysis of psychotherapy and medication in unipolar depression and dysthymia
Imel, Z. E., Malterer, M. B., McKay, K. M., & Wampold, B. E. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.018 · Cited by 158 · cited 2×
“[27,38,65,66], pointing instead to mechanisms that are shared amongst various illnesses and treatments.”
BackgroundTracking thoughts: Exploring the neural architecture of mental time travel during mind-wandering
Karapanagiotidis, T., Bernhardt, B. C., Jefferies, E., & Smallwood, J. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.12.031 · Cited by 155 · cited 1×
“when individuals are not focused on the immediate environment [150], but rather engaged in self-referential thought [151], or mental time travel [152], for example.”
BackgroundBudd, R., & Hughes, I. (2009) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.648 · Cited by 149 · cited 1×
“regardless of that theory’s actual veracity [86].”
Sacred Knowledge: Psychedelics and Religious Experiences
Richards, W. (2015) · Columbia University Press eBooks · doi:10.7312/columbia/9780231174060.001.0001 · Cited by 148
Optimizing outcomes in depression: focus on antidepressant compliance
Keller, M. B., Hirschfeld, R. M. A., Demyttenaere, K., & Baldwin, D. S. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00001 · Cited by 142 · cited 1×
“marked by poor adherence in approximately 50% of patients [49], partly due to the delayed onset of benefits [53], the need for daily dosing even after symptoms have improved [49,52], impairments in motivation and self-care intrinsic to disorders”
BackgroundA meta-analytic review of psychodynamic therapies for anxiety disorders
Keefe, J. R., McCarthy, K. S., Dinger, U., Zilcha‐Mano, S., & Barber, J. P. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2014.03.004 · Cited by 138
Cristea, I. A., Huibers, M. J. H., David, D., Hollon, S. D., Andersson, G., & Cuijpers, P. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.08.003 · Cited by 135 · cited 2×
“antidepressants may even reduce the use of immature defense mechanisms and dysfunctional thinking [94,95], key”
BackgroundNiciu, M. J., Shovestul, B. J., Jaso, B. A., Farmer, C., Luckenbaugh, D. A., Brutsche, N. E., Park, L. T., Ballard, E. D., & Zarate, C. A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.049 · Cited by 132
Robertson, D. (2019) · Routledge eBooks · doi:10.4324/9780429268700 · Cited by 132
Craighead, W. E., & Dunlop, B. W. (2014) · Annual Review of Psychology · doi:10.1146/annurev.psych.121208.131653 · Cited by 128 · cited 3×
“Evidence-based psychotherapies like Cognitive Behavioral Therapy (CBT) are generally accepted to be equivalently efficacious for depressive disorders as antidepressants, except for persistent depressive disorder [67].”
BackgroundImpact of the physical environment of psychiatric wards on the use of seclusion
van der Schaaf, P. S., Dusseldorp, E., Keuning, F. M., Janssen, W. A., & Noorthoorn, E. O. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.118422 · Cited by 127
The Use of Music in Psychedelic (LSD) Psychotherapy
Bonny, H. L., & Pahnke, W. N. (1972) · Journal of Music Therapy · doi:10.1093/jmt/9.2.64 · Cited by 124
Therapeutic infusions of ketamine: do the psychoactive effects matter?
Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.12.019 · Cited by 123
The early use of MDMA (‘Ecstasy') in Psychotherapy (1977–1985)
Passie, T. (2018) · Drug Science Policy and Law · doi:10.1177/2050324518767442 · Cited by 116 · cited 1×
“trolled substance in the United States in 1985 due to widespread recreational use [165], it was employed in thousands of therapy sessions [166].”
BackgroundL.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug.
Busch, A., & Johnson, W. (1950) · PubMed · Cited by 115
Recognition of psychotherapy effectiveness: The APA resolution.
Campbell, L. F., Norcross, J. C., Vasquez, M. J. T., & Kaslow, N. J. (2013) · Psychotherapy · doi:10.1037/a0031817 · Cited by 114 · cited 2×
“Psychotherapy has no single definition but may be understood as an interpersonal intervention that relies on repeated encounters, a healing relationship, and a particular explanatory model, all within a structured therapeutic frame [65,78,79].”
BackgroundHealing Environment in Psychiatric Hospital Design
Gross, R., Sasson, Y., Zarhy, M., & Zohar, J. (1998) · General Hospital Psychiatry · doi:10.1016/s0163-8343(98)00007-3 · Cited by 111
Carhart-Harris, R. L., Wall, M. B., Erritzoe, D., Kaelen, M., Ferguson, B., De Meer, I., Tanner, M., Bloomfield, M., Williams, T. M., Bolstridge, M., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001405 · Cited by 108 · cited 1×
“connectivity between the hippocampus and amygdala [162].”
Hpa axis related genes and response to psychological therapies: Genetics and epigenetics
Roberts, S., Keers, R., Lester, K. J., Coleman, J. R. I., Breen, G., Arendt, K., Blatter‐Meunier, J., Cooper, P., Creswell, C., Fjermestad, K., et al. (2015) · Depression and Anxiety · doi:10.1002/da.22430 · Cited by 107
Hirshfeld, A. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1448 · Cited by 107
Steinkamp, J. M., Goldblatt, N., Borodovsky, J. T., LaVertu, A., Kronish, I. M., Marsch, L. A., & Schuman-Olivier, Z. (2019) · JMIR Mental Health · doi:10.2196/12493 · Cited by 106 · cited 2×
“marked by poor adherence in approximately 50% of patients [49], partly due to the delayed onset of benefits [53], the need for daily dosing even after symptoms have improved [49,52], impairments in motivation and self-care intrinsic to disorders”
BackgroundRole of Inflammation in Depression and Treatment Implications
Felger, J. C. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_166 · Cited by 103 · cited 1×
“Although uncertainties remain, recent explanatory models tend to emphasize the roles of neuroplasticity [63], inflammation [64], and glutamatergic systems in depression [31].”
BackgroundAntidepressants: From MAOIs to SSRIs and more
Yeragani, V., Ramachandraih, C., Subramanyam, N., Bar, K., & Baker, G. B. (2011) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.82567 · Cited by 100 · cited 3×
“take inhibitors (SSRIs), the serotonin-norepinephrine reuptake inhibitors (SNRIs), and a variety of other molecules [30,34].”
BackgroundNutt, D., & Goodwin, G. M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.05.004 · Cited by 99
The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review
Demyttenaere, K., & Van Duppen, Z. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy052 · Cited by 98 · cited 1×
“ing treatments are generally considered effective [5], treatment-resistance is a common and increasing clinical phenomenon [6,7].”
BackgroundPalmer, S. C., Natale, P., Ruospo, M., Saglimbene, V. M., Rabindranath, K. S., Craig, J. C., & Strippoli, G. F. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004541.pub3 · Cited by 96
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95 · cited 1×
“disadvantages include both short-term and long-term side effects [49], which possibly continue for years following drugdiscontinuation [50], and benefits that may not persist after treatment discontinuation [50,51].”
BackgroundHendricks, P. S., Crawford, M. S., Cropsey, K. L., Copes, H., Sweat, N. W., Walsh, Z., & Pavela, G. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117735685 · Cited by 93 · cited 1×
“(5HT2A) receptor agonists, whereas others describe this class as classic (or classical) psychedelics [22,23].”
BackgroundPsychological Aspects of the Lsd Treatment of the Neuroses
Sandison, R. A. (1954) · Journal of Mental Science · doi:10.1192/bjp.100.419.508 · Cited by 92 · cited 1×
“the environment, and the patient’s unique psychic structure [131,132].”
BackgroundHendricks, P. S., Clark, C. B., Johnson, M. W., Fontaine, K. R., & Cropsey, K. L. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113513851 · Cited by 88 · cited 2×
“chedelic use and less criminal recidivism (in contrast to all other drugs [217]) and less intimate partner violence”
BackgroundThe Past and Future of Psychedelic Science: An Introduction to This Issue
Doblin, R. E., Christiansen, M., Jerome, L., & Burge, B. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1606472 · Cited by 87 · cited 1×
“1938, and its psychoactive effects were discovered during his accidental ingestion 5 years later [118].”
BackgroundSelf-citationLeuchter, A. F., Hunter, A. M., Tartter, M., & Cook, I. A. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.140343 · Cited by 86 · cited 2×
“reported strength of therapeutic alliance [99,101], much like psychotherapy [85].”
Background'Doing the right thing': factors influencing GP prescribing of antidepressants and prescribed doses
Johnson, C. F., Williams, B., MacGillivray, S. A., Dougall, N. J., & Maxwell, M. (2017) · BMC Family Practice · doi:10.1186/s12875-017-0643-z · Cited by 86 · cited 1×
“pressants are preferred and effective treatments for many patients [27,34,36–38], fit well into a medical model of mental healthcare [39,40], and are cost-effective treatments for anxiety and depression [41–43].”
BackgroundRobertson, D. (2019) · Cited by 86
Prosocial effects of MDMA: A measure of generosity
Kirkpatrick, M., Delton, A. W., Robertson, T. E., & de Wit, H. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115573806 · Cited by 85 · cited 1×
“One of the results appears to be greater prosocial behavior [163,164].”
BackgroundDakwar, E., Nunes, E. V., Hart, C. L., Hu, M. C., Foltin, R. W., & Levin, F. R. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.005 · Cited by 85 · cited 1×
“Rather, evidence suggest that the experiences induced by ketamine – much like the psychedelics – within a psychotherapeutic frame least partially mediate its efficacy against addiction [235].”
BackgroundTibetan Buddhist Medicine and Psychiatry: The Diamond Healing
Martin, D., & Clifford, T. (1986) · Journal of the American Oriental Society · doi:10.2307/601638 · Cited by 84
Morrison, A. P., Law, H., Carter, L., Sellers, R., Emsley, R., Pyle, M., French, P., Shiers, D., Yung, A. R., Murphy, E. K., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30096-8 · Cited by 84 · cited 1×
“We elected to focus on how antidepressants combine with psychotherapy as this combination has been studied in depth [5,24], and its benefits are better established than other psychotherapy-medication combinations, such as benzodiazepines and antipsychotics [25,26].”
BackgroundD‐Lysergic acid diethylamide (LSD): A review of its present status
Hoffer, A. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196562183 · Cited by 83 · cited 1×
“a unique way, non-verbally supporting and enhancing patient experiences [204].”
BackgroundDiscontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience
Fava, G. A., & Belaise, C. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000492693 · Cited by 77 · cited 1×
“tinuation – associated with risks including suicide [59] – so as to avoid potential interactions such as serotonin syndrome [137].”
BackgroundShould treatment for depression be based more on patient preference?
Winter, S., & Barber, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s52746 · Cited by 73
Hartberg, J., Garrett-Walcott, S., & Gioannis, A. D. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4786-3 · Cited by 71
PSYCHOLOGICAL CHANGES IN NORMAL AND ABNORMAL INDIVIDUALS UNDER THE INFLUENCE OF SODIUM AMYTAL
Lindemann, E. (1932) · American Journal of Psychiatry · doi:10.1176/ajp.88.6.1083 · Cited by 70 · cited 1×
“For example, ‘narcoanlaysis’ referred to the practice of utilizing barbiturates to facilitate psychoanalysis [127], and various other agents were studied as adjuncts of psychotherapy, such as nitrous oxide, ether, and carbon dioxide [128].”
BackgroundFaria, V., Gingnell, M., Hoppe, J. M., Hjorth, O., Alaie, I., Frick, A., Hultberg, S., Wahlstedt, K., Engman, J., Månsson, K. N. T., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.031 · Cited by 70
NHS prescribed record number of antidepressants last year
Iacobucci, G. (2019) · BMJ · doi:10.1136/bmj.l1508 · Cited by 70 · cited 1×
“American adults estimated to have filled a prescription for an antidepressant in 2013 [35,57].”
BackgroundChiarotti, F., Viglione, A., Giuliani, A., & Branchi, I. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.35 · Cited by 68 · cited 1×
“antidepressants increases sensitivity to the environment [103,104].”
Stahl, S. M. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01301.x · Cited by 67 · cited 1×
“Psychotherapy’s capacity to modify gene expression has prompted renowned psychopharmacologist Stephen Stahl to analogize it as an ‘epigenetic drug’ [117].”
BackgroundChanges in CREB Phosphorylation and BDNF Plasma Levels during Psychotherapy of Depression
Koch, J. M., Hinze-Selch, D., Stingele, K., Huchzermeier, C., Göder, R., Seeck-Hirschner, M., & Aldenhoff, J. B. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000209350 · Cited by 67 · cited 1×
“resilience have also been found with successful psychotherapy [114], as have epigenetic changes in both children and”
BackgroundWalsh, Z., Hendricks, P. S., Smith, S., Kosson, D. S., Thiessen, M. S., Lucas, P., & Swogger, M. T. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116642538 · Cited by 64
Psychotherapy: Definitions, Mechanisms of Action, and Relationship to Etiological Models
Brent, D. A., & Kolko, D. J. (1998) · Research on Child and Adolescent Psychopathology · doi:10.1023/a:1022678622119 · Cited by 62 · cited 1×
“Psychotherapy has no single definition but may be understood as an interpersonal intervention that relies on repeated encounters, a healing relationship, and a particular explanatory model, all within a structured therapeutic frame [65,78,79].”
BackgroundWhy More Psychological Therapy Would Cost Nothing
Layard, R., & Clark, D. M. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.01713 · Cited by 60 · cited 1×
“[73,74], which demonstrates that providing psychotherapy at a population level is feasible.”
BackgroundBrexanolone: First Global Approval
Scott, L. J. (2019) · Drugs · doi:10.1007/s40265-019-01121-0 · Cited by 60 · cited 1×
“With some notable exceptions, like brexanolone infusions for postpartum depression and vortioxetine for major depressive disorder [17,18], these developments appear to represent the only recent”
BackgroundAntidepressants for irritable bowel syndrome—A systematic review
Kułak-Bejda, A., Bejda, G., & Waszkiewicz, N. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.05.014 · Cited by 59 · cited 1×
“treat a wide variety of conditions beyond depression, including a wide range of anxiety disorders [27], neuropathic pain [28], and irritable bowel syndrome [29].”
BackgroundDefense mechanisms and personality in depression
Mullen, L. S., Blanco, C., Vaughan, S. C., Vaughan, R., & Roose, S. P. (1999) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1999)10:4<168::aid-da5>3.0.co;2-5 · Cited by 58 · cited 2×
“antidepressants may even reduce the use of immature defense mechanisms and dysfunctional thinking [94,95], key”
BackgroundCarbon dioxide therapy: A neurophysiological treatment of nervous disorders.
Meduna, L. J. (1950) · Charles C Thomas Publisher eBooks · doi:10.1037/13238-000 · Cited by 57
Ramsberg, J., Asseburg, C., & Henriksson, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042003 · Cited by 57
Transpersonal psychology, physical health, and mental health: Theory, research, and practice.
Elmer, L. D., MacDonald, D. A., & Friedman, H. L. (2003) · The Humanistic Psychologist · doi:10.1080/08873267.2003.9986929 · Cited by 55 · cited 1×
“Contributing to the development of movements like transpersonal psychology [184], spirituality was often embraced rather”
BackgroundKolp, E., Friedman, H. L., University of Florida, Krupitsky, E., St. Petersburg State Pavlov Medical University, Jansen, K., Hospital, A., Sylvester, M., Young, M. S., University of South Florida, et al. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.84 · Cited by 54
Specific Techniques Vs. Common Factors? Psychotherapy Integration and its Role in Ethical Practice
Brown, J. (2015) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.2015.69.3.301 · Cited by 51
Barrett, F. S., Preller, K. H., Herdener, M., Janata, P., & Vollenweider, F. X. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhx257 · Cited by 51 · cited 1×
“[33,120], but 5HT2A (partial) agonism is central to its effects, as demonstrated by the nearly complete extinction of psychological effects by 5HT2A antagonists like ketanserin [133,134].”
BackgroundRoss, E. L., Vijan, S., Miller, E. M., Valenstein, M., & Zivin, K. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1480 · Cited by 50
Predicting antidepressant treatment outcome based on socioeconomic status and citalopram dose
Viglione, A., Chiarotti, F., Poggini, S., Giuliani, A., & Branchi, I. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0080-6 · Cited by 48 · cited 1×
“antidepressants increases sensitivity to the environment [103,104].”
Watanabe, N., Churchill, R., & Furukawa, T. A. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-18 · Cited by 46
Charney, D. A., Heath, L. M., Zikos, E., Palacios‐Boix, J., & Gill, K. J. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12802 · Cited by 45
Kolp, E., Young, M. S., Florida Mental Health Institute of University of South Florida, Friedman, H., University of Florida, Krupitsky, E., St. Petersburg State Pavlov Medical University, Jansen, K., O’Connor, L.-A., & Argosy University (2007) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2007.26.1.1 · Cited by 45
A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State
Lowe, L. M., Peterson, B. L., & Couper, F. J. (2015) · Journal of Analytical Toxicology · doi:10.1093/jat/bkv092 · Cited by 44 · cited 1×
“These risks appear to be substantially greater in relatively novel psychedelic analogs [221].”
BackgroundCooper, M. D., Rosenblat, J. D., Cha, D. S., Lee, Y., Kakar, R., & McIntyre, R. S. (2017) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2016.1139747 · Cited by 41
Biological v. psychosocial treatments: a myth about pharmacotherapy v. psychotherapy
Prosser, A., Helfer, B., & Leucht, S. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.178368 · Cited by 41
Castelnuovo, G., Pietrabissa, G., Cattivelli, R., Manzoni, G. M., & Molinari, E. (2016) · Frontiers in Psychology · doi:10.3389/fpsyg.2016.00563 · Cited by 40 · cited 1×
“often lacking [71], partly because of greater upfront costs and the (generally false) perception of policy-makers that it is not cost-effective [71,72].”
BackgroundPsychotropic Drug???Induced Sexual Function Disorders: Diagnosis, Incidence and Management
Clayton, D. O., & Shen, W. W. (1998) · Drug Safety · doi:10.2165/00002018-199819040-00005 · Cited by 38 · cited 1×
“such as depression [54], and potential side-effects like impaired sexual functioning [55].”
BackgroundKolp, E., Friedman, H. L., Young, M. S., & Krupitsky, E. (2006) · The Humanistic Psychologist · doi:10.1207/s15473333thp3404_7 · Cited by 38 · cited 1×
“successfully used in the treatment of depression/anxiety [181], PTSD [229], as well as alcohol [230], heroin [231], and cocaine addiction [232].”
MethodDepression Treatment Preferences of VA Primary Care Patients
Dobscha, S. K., Corson, K., & Gerrity, M. (2007) · Psychosomatics · doi:10.1176/appi.psy.48.6.482 · Cited by 36
A century of psychotherapy, 1860–1960.
Cautin, R. L. (2011) · American Psychological Association eBooks · doi:10.1037/12353-001 · Cited by 36 · cited 1×
“Breuer and Sigmund Freud’s development of psychoanalysis [80], Philippe Pinel’s moral treatment [81], or, more broadly, to diverse traditions including Western philosophy [82], Eastern religions [83], and shamanism [78].”
BackgroundHigh-Dose Ketamine Infusion for the Treatment of Posttraumatic Stress Disorder in Combat Veterans
Ross, C., Jain, R., Bonnett, C. J., & Wolfson, P. (2019) · Annals of Clinical Psychiatry · doi:10.1177/154733251903100411 · Cited by 36 · cited 9×
“successfully used in the treatment of depression/anxiety [181], PTSD [229], as well as alcohol [230], heroin [231], and cocaine addiction [232].”
MethodInfluentialReview of antidepressants in the treatment of neuropathic pain
Baltenberger, E. P., Buterbaugh, W. M., Martin, B. S., & Thomas, C. J. (2015) · Mental Health Clinician · doi:10.9740/mhc.2015.05.123 · Cited by 35 · cited 1×
“treat a wide variety of conditions beyond depression, including a wide range of anxiety disorders [27], neuropathic pain [28], and irritable bowel syndrome [29].”
Background
Research works printed but not linked: 22
- Friedrich MJ., 2017, JAMA, 317, 1517
- Bahr R, 2019, P T Peer-Rev. J. Formul. Manag, 44, 340
- Lee MA, 1992, Acid dreams: the complete social history of LSD: the CIA, the sixties, and beyond. Rev. Evergreen ed
- Andrews PW, Front. Psychol
- Kirsch I, Front. Psychiatry
- Hengartner MP. Methodological Flaws, 2017, Front. Psychiatry, 8:275
- Østergaard SD, 2017, Acta Neuropsychiatr
- Sansone RA, 2012, Clin Neurosci, 9, 41
- Davies J, 2019, Behav, 97, 111
- Freud S, 2007, The history of the psychoanalytic movement
- Kirsch I, 2002, Food and Drug Administration. Prev. Treat, 5
- Zilcha-Mano S, 2015, Psychosom, 84, 177
- Kaplan RM, Int J Humanit Soc Sci Educ
- Ban TA, 2007, Neuropsychiatr Dis Treat, 3, 495
- Hurth KP, 2020, Care Med, 1
- Glue P, 20, J Psychopharmacol (Oxf.)
- Kasprow MC, 1999, J Psychother P Res, 8, 12
- Taking Psychedelics BI, 2018, Med, 21, 417
- Winnicott DW, 1953, Int J Psychoanal, 34, 89
- Thiessen MS, 2018, J Psychopharmacol (Oxf.), 026988111877178
- Ross C, 2019, Ann Clin Psychiatry, 31, 271
- Sos P, 2013, Neuro Endocrinol Lett, 34, 287
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Schimmers, N., Breeksema, J. J., Smith-Apeldoorn, S. Y., Veraart, J., van den Brink, W., & Schoevers, R. A. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06027-y · Cited by 162
“Ketamine seems to be mainly offered as a stand-alone pharmacological treatment, like conventional antidepressants (Greenway et al., 2020).”
BackgroundThe molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
Metadata
- Authors
- Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A.
- Affiliations
- McGill University (CA)
- Data Services, MAPS Public Benefit Corporation
- Project New Day, Psychedelic.Support
- Corresponding author
- Greenway, Kyle T.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2020-06-01
- Volume
- 13
- Issue
- 6
- Pages
- 655-670
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W3031742716
- Semantic Scholar
- 82347e6b820aa8a3f6105d3ae1955c2a08f52eae
- Cited by
- 94
- References
- 217
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 27 · 2023: 14 · 2022: 13 · 2021: 10 · 2020: 1
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- psychedelic-assisted psychotherapy, antidepressants, therapeutic mechanisms, MDMA, ketamine, psychedelics, environmental sensitivity, neurochemical changes, psychopathology
- MeSH terms
- Animals, Mental Disorders, Combined Modality Therapy, Hallucinogens, Humans, Psychotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.